Cantor maintains Neutral rating on Universal Health

Cantor Fitzgerald maintains a Neutral rating on Universal Health (UHS) with a $227 price target correcting an earlier research note which incorrected stated the shares were downgraded to Underweight. The company’s pathway to EBITDA growth in 2026 versus 2025 is more clear post the Q2 report, excluding the expiration of premium enhanced subsidies on marketplace, the analyst tells investors in a research note. Cantor is now more optimistic on Universal Health’s EBITDA growth in 2026 considering the $50M tailwind from Cedar Hill recovery.